Immunotherapy in Second-Line Advanced Bladder Cancer – OncLive
OncLive |
Immunotherapy in Second-Line Advanced Bladder Cancer
OncLive Daniel J. George, MD: 2017 into 2018 is going to be a transition period in bladder cancer, particularly for patients who are in the second-line setting. Still today, many of our patients are getting a platinum-based chemotherapy in either the … |
